Advanced gastrointestinal neuroendocrine tumours respond unusually well to new treatment: results from the NETTER-1 trial
Patients with advanced gastrointestinal neuroendocrine tumours (NETs) have limited treatment options and there are few oncologists who are specialised in this relatively rare disease. But now results from a multi-centre randomised international trial of an innovative treatment show a marked improvement in the length of time patients with...
Read More
